RxDoctor Payments Data

Ramin Khalili, MD

Urology · Pasadena, CANPI 1689784449

Payments from drug & device makers

$20,263in general payments, 2019–2025

Across 501 payments — averaging $40.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$3K
  • Teleflex LLC$2K
  • Procept Biorobotics Corporation$2K
  • Neotract Inc.$2K
  • Johnson & Johnson$1K
  • AbbVie$986
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$2,67213%
  • Speaking & faculty fees$3502%
  • Travel & lodging$2,48412%
  • Food & beverage$14,52872%
  • Education$2291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,263 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$958,639
Medicare patients
1,408
Services billed
11,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron144$137,781
MyrbetriqMirabegron163$132,461
Tamsulosin Hcl723$13,119
Dutasteride235$9,104
Estradiol119$9,027
Finasteride454$7,005
Methenamine Hippurate60$6,334
XyostedTestosterone Enanthate11$6,251
Potassium Citrate ErPotassium Citrate51$5,685
Alfuzosin Hcl ErAlfuzosin Hcl295$5,519
Fesoterodine Fumarate ErFesoterodine Fumarate28$5,006
Silodosin46$4,032
Trospium Chloride ErTrospium Chloride15$3,529
Solifenacin Succinate36$3,337
Tolterodine Tartrate ErTolterodine Tartrate32$2,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$730$137,781144 claims
Astellas Pharma US IncMyrbetriq$840$132,461163 claims
Antares Pharma, Inc.Xyosted$405$6,25111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.

Other urology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →